Genenta Science S.p.A. (NASDAQ:GNTA) Short Interest Update

Genenta Science S.p.A. (NASDAQ:GNTA) was the recipient of a significant increase in short interest in December. As of December 15th, there was short interest totalling 3,100 shares, an increase of 121.4% from the November 30th total of 1,400 shares. Based on an average daily volume of 13,600 shares, the short-interest ratio is presently 0.2 days.

Hedge Funds Weigh In On Genenta Science

An institutional investor recently bought a new position in Genenta Science stock. AlTi Global Inc. purchased a new stake in Genenta Science S.p.A. (NASDAQ:GNTA) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 200,288 shares of the company’s stock, valued at approximately $621,000. AlTi Global Inc. owned about 1.10% of Genenta Science at the end of the most recent quarter. Hedge funds and other institutional investors own 15.13% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $25.00 target price on shares of Genenta Science in a report on Wednesday, October 2nd.

Genenta Science Trading Down 5.2 %

NASDAQ GNTA opened at $4.88 on Friday. The stock has a 50 day moving average price of $5.10 and a 200-day moving average price of $4.43. Genenta Science has a one year low of $2.20 and a one year high of $7.28.

About Genenta Science

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.